The ProgRET Marie-Curie doctoral network held a meeting, including two workshops in complementary skills, as well as research training in Montpellier, organized by the Institute for Neurosciences and Inserm Occitanie Méditerranée. The program consisted of a highly interactive Excellence in Science Communication workshop, a thought-provoking session on Fundraising and Patient Engagement, animal and cellular models to study autosomal dominant diseases, and a great research training session. This event was a great success thanks to the highly talented and enjoyable group of doctoral fellows!

We are thrilled to announce that all 10 PhD students have now been successfully recruited for our European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases. These talented researchers will begin their work between September 1 and October 1, and they are eager to embark on this journey of training, discovery and innovation.
To mark the official start of our project, we will be hosting a kick-off meeting in Ghent, Belgium, on Monday, September 30. This event will bring together the PhD students, their Principal Investigators, our Associated Partners, and external advisors, providing an excellent opportunity for introduction, networking, collaboration, and the sharing of ideas. For those unable to attend in person, we have made arrangements to accommodate online participation, ensuring that everyone can contribute to this important meeting.
Following the kick-off, we will be holding the first set of training events for our PhD candidates from October 1 to 3. These sessions will include introductory lectures on the Genetics, Genomics, and Pathways of Inherited Retinal Diseases (IRD), laying the foundational knowledge necessary for their research. Additionally, the students will participate in a workshop on Research Integrity and Ethics, which is crucial for guiding their future work.
We look forward to welcoming everyone to Ghent and to the start of this exciting research and training initiative. Together, we will make significant strides in understanding and treating retinal diseases in Europe, and to translate research findings to healthcare and society.

ProgRET is a Marie Skłodowska-Curie Doctoral Network (2024-2027), offering 10 PhD positions, who will address the knowledge gaps to understanding, diagnosing and treating Inherited Retinal Diseases. The objective of ProgRET is to train a new generation of vision researchers specialising in inherited retinal diseases (IRD).
Eye diseases are among the most common inherited human disorders. Vision research has often blazed a trail for many disciplines to follow, giving a lead in multi-omics, stem cell biology, genome editing, animal models of disease, and the development of novel therapeutic approaches such as gene therapy. In recent years, human geneticists, have identified a large proportion of the genes implicated in IRD. Despite this progress the most important challenges in the IRD field relate to the diagnosis, understanding as well as therapy development of autosomal dominant IRD (adIRD). There are an estimated 925,000 affected individuals worldwide, representing 25%–40% of IRD. As we have demonstrated an emerging role for complex structural variants (SVs) and defects in non-coding regions such as non-coding RNAs and cis-regulatory elements in adIRD, we hypothesize that these may explain unsolved IRD cases and may represent novel targets for intervention.
The objective of ProgRET is to conduct advanced vision research that addresses the knowledge gaps to understanding, diagnosing and treating autosomal dominant inherited retinal disease (adIRD), using innovative approaches related to genomics, transcriptomics, epigenomics, multi-omics, bioinformatics, gene regulation, retinal stem cell models, organoids, aquatic animal disease models, and therapy development.
We will pursue the following specific research objectives: 1. To understand mechanisms of adIRD using retinal stem cell and aquatic animal models; 2. To advance diagnostics in adIRD using a single-molecule multi-omics framework; 3. To develop novel therapeutics for adIRD using RNA therapy and genome editing.
Application Deadline: 26 May 2024 - 23:59 (Europe/Paris)
 
Researcher Profile: First Stage Researcher (R1)
 
Research Field: ’(Human) Genetics’, ’Molecular Biology’,  ’Biomedical research’, ’translational research’, ’integrative omics’, ’(Applied) Bioinformatics’.
 
Type of Contract: Temporary
 
Job Status: Full-time
 
Offer Starting Date: Ranging from 1 September - 1 November 2024